The clinical-trial supplies (CTS) arm of UK-based specialist pharmaceuticals and services group Clinigen has extended and expanded the exclusive agreement it signed with Accord Healthcare in June 2012 to distribute the latter’s injectable oncology portfolio for studies across the European Union.

The agreement now includes the orally administered chemotherapeutic capecitabine, adding to an EU portfolio of more than 15 injectable oncology products distributed by Clinigen CTS for Accord to manufacturers, contract research organisations, clinical re-packagers and other specialist providers for use as comparator, co-therapy, rescue and adjunctive drugs in clinical trials.

In June 2013 Clinigen CTS renewed its agreement with Accord, a wholly owned marketing subsidiary of India’s Intas Pharmaceuticals, to supply these products for a further two years. Clinigen is the sole point of contact for all associated clinical-trial supply enquiries and orders.

The Capecitabine Accord tablet, which is a hybrid generic version of Xeloda (Roche), is available in a new strength of 300mg as well as existing strengths of 150mg and 500mg. It was launched in Europe last December.

Key asset

“Capecitabine is a key product for Accord,” commented Daniel Green, the company’s hospital director, UK & Ireland.

“We see clinical trials as an important area into which we can supply the drug and extending our exclusive agreement with Clinigen will allow us to maximise the impact and potential of the product in this area.”